ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

FTC Seeks Additional Info From Teva, Cephalon Regarding Merger

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and acquisition target Cephalon Inc. (CEPH) each received a request to provide additional information to the U.S. Federal Trade Commission related to a pending $6.8 billion deal between the firms. Israel-based Teva, which trumped a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) in agreeing to buy Cephalon last month, said it had expected the request. The parties have been cooperating with the FTC staff since shortly after the bid was announced, according to Teva, which said it intends to win clearance "as promptly as possible." Teva on Monday said it continues to expect the deal to be completed in the third quarter, following clearance from U.S. and European regulators, as well as winning approval of Cephalon shareholders. Teva's American depositary shares were recently up 0.4% to $49.35 in after-hours trading. -By John Kell, Dow Jones Newswires; 212-416-2480; john.kell@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
11/25/201419:25:05Jefferies Bumps Up Against Big Rivals as It Looks to Expand
11/25/201418:53:14CEOs' Test: Contending With Activist Investors
11/20/201412:41:11Valeant Sets $2 Billion Buyback Plan After Losing Allergan
11/19/201419:15:16For Allergan Suitors, Unorthodox Alliance Proved Unwieldy
11/18/201419:55:17Goldman Hits Mother Lode on Deals
11/18/201418:50:13Ackman Drops Push for Allergan Holder Meeting--2nd Update
11/18/201418:40:32Ackman Drops Push for Allergan Holder Meeting--Update
11/18/201408:07:30Zoetis Unveils $500 Million Buyback Plan
11/17/201420:01:10Deal Boom Feeds on Surging Stocks
11/17/201418:16:19Actavis To Buy Allergan In $66 Billion Deal--5th Update
11/17/201416:28:40Actavis To Buy Allergan in $66 Billion Deal -- 5th Update
11/17/201415:35:37Ackman, Valeant Can't Justify Topping Actavis Bid for Allergan
11/17/201410:16:39Actavis To Buy Allergan In $66 Billion Deal--4th Update
11/17/201410:07:59Actavis To Buy Allergan In $66 Billion Deal--3rd Update
11/17/201410:01:21Actavis To Buy Allergan In $66 Billion Deal--2nd Update
11/17/201409:52:21Actavis To Buy Allergan In $66 Billion Deal--Update
11/17/201409:29:21MARKET SNAPSHOT: U.S. Stocks: Futures Lower; Industrial Production...
11/17/201408:07:11MARKET SNAPSHOT: U.S. Stocks: Futures Lower After Japan Falls...
11/17/201402:57:05Valeant Buys Nicox's Ophtalmic Diagnostics for Up to $20 Million
11/16/201419:54:13Allergan, Actavis Near Deal -- 3rd Update

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad